Equities

Zevra Therapeutics Inc

Zevra Therapeutics Inc

Actions
  • Price (EUR)8.20
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change+107.07%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6883112
Total Receivables, Net178.301.53
Total Inventory------
Prepaid expenses1.821.691.18
Other current assets, total----0
Total current assets8793115
Property, plant & equipment, net1.531.782.03
Goodwill, net4.700--
Intangibles, net690--
Long term investments02015
Note receivable - long term------
Other long term assets9.940.720.44
Total assets172115133
LIABILITIES
Accounts payable143.610.52
Accrued expenses153.042.88
Notes payable/short-term debt000
Current portion long-term debt/capital leases380.010.02
Other current liabilities, total7.075.370.82
Total current liabilities74124.23
Total long term debt5.07130.01
Total debt43130.02
Deferred income tax------
Minority interest------
Other liabilities, total32151.59
Total liabilities110405.82
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital473436397
Retained earnings (accumulated deficit)(400)(354)(267)
Treasury stock - common(11)(7.54)(2.81)
Unrealized gain (loss)------
Other equity, total(0.04)0.11--
Total equity6275127
Total liabilities & shareholders' equity172115133
Total common shares outstanding423535
Treasury shares - common primary issue1.580.910.32
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.